HealthcareServices

Glycomic Therapeutics Global Forecast: Market to Scale Up to $424.67 Billion by 2030 at 17.6% CAGR

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the glycomic therapeutics market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Glycomic Therapeutics Market expected to grow between 2026 and 2030?

The glycomic therapeutics market has experienced significant expansion recently. Its size is projected to increase from $189.51 billion in 2025 to $221.98 billion in 2026, showing a compound annual growth rate (CAGR) of 17.1%. This historical growth can be attributed to progress in glycobiology studies, the development of enzyme therapies, approvals for rare disease medications, financial support for academic research, and the expansion of biologics production.

The glycomic therapeutics market is projected to undergo significant expansion in the coming years. By 2030, its valuation is anticipated to reach $424.67 billion, achieving this with a compound annual growth rate (CAGR) of 17.6%. This expected increase can be primarily attributed to the widespread adoption of precision medicine, breakthroughs in glycan biomarker discovery, the expansion of orphan drug pipelines, continuous innovation in synthetic biology, and heightened investment in pharmaceutical research. Key developments during this period are expected to include the broader advancement of glycan-based drug development, an escalating focus on immune modulation therapies, the increasing utilization of enzyme replacement therapies, rising research efforts dedicated to rare and metabolic diseases, and the overall growth of synthetic glycan technologies.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11894&type=smp

Which Drivers Are Influencing Market Acceleration In The Glycomic Therapeutics Market?

The growing incidence of diabetes is anticipated to stimulate expansion within the glycomic therapeutics market. This chronic medical condition impairs the body’s ability to regulate blood sugar levels. Alterations in glycans are noted in diabetes, contributing to insulin resistance and other metabolic issues, with specific glycan patterns functioning as biomarkers for diagnosis, progression prediction, and treatment monitoring. As an illustration, in March 2025, GOV.UK, a UK-based non-profit government organization, reported that the prevalence of type 2 diabetes in adults aged **17** and over in **England**, as recorded by GPs, stood at **7.0%** in **March 2024**, which marked an increase from **6.8%** in **March 2023**. Thus, the rising occurrence of diabetes is acting as a catalyst for the glycomic therapeutics market’s growth.

What Segments Are Identified Within The Structure Of The Glycomic Therapeutics Market?

The glycomic therapeutics market covered in this report is segmented –

1) By Class: Isolated, Synthetic

2) By Structures: Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins And Heparin Based Glycans, Targeting Glycosphingolipids, Other Structures

3) By Mode Of Action: Inhibits Neuraminidase, Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate, Erythropoietin And Enzyme Replacement Therapy (ERT), Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthase, Interleukin 1, 2 And 3, Beta And Gamma Interferons, Other Mode Of Action

4) By Indications: Thrombosis And Chemoprophylaxis, Anemia, Anti-Adhesive And Anti-Inflammatory, Cataracts, Gaucher’s Disease, Mps-1 And IV, Cancer, Alzheimer’s Disease, Influenza Type A And B, Other Indications

Subsegments:

1) By Isolated: Natural Glycans, Glycan Derivatives, Glycoproteins

2) By Synthetic: Chemically Synthesized Glycans, Recombinant Glycans, Glycopeptides

What Trends Are Reshaping The Dynamics Of The Glycomic Therapeutics Market?

Companies active in the glycomic therapeutics market are concentrating on creating novel solutions, including glyco-immune checkpoint inhibitors, to combat tumor immune evasion and improve treatment effectiveness. These inhibitors are treatments intended to obstruct immunosuppressive sugar molecules present on cancer cells, thereby assisting the immune system in more effectively identifying and targeting tumors. As an example, Palleon Pharmaceuticals Inc., a US-based biopharmaceutical company, reported in June 2023 that the initial patient received treatment within the combination therapy group of the Phase 1/2 GLIMMER-01 clinical trial, which is assessing their primary glyco-immunology candidate E-602 combined with cemiplimab (Libtayo®) for individuals with advanced cancers. The study investigates E-602 both alone and alongside cemiplimab to determine its safety, pharmacodynamics, and ability to fight tumors. E-602 functions as a pioneering glyco-immune checkpoint inhibitor engineered to enzymatically break down immunosuppressive sialoglycans on tumor and immune cells, with the goal of re-establishing antitumor immunity.

Which Key Players Are Driving Competition In The Glycomic Therapeutics Market?

Major companies operating in the glycomic therapeutics market are F Hoffmann-La Roche Ltd., Sanofi SA, Thermo Fisher Scientific Inc., GlaxoSmithKline plc, Merck KGaA, Agilent Technologies Inc., AMS Bio, Shimadzu Corporation, Waters Corporation, Bruker Corporation, BioMarin Pharmaceutical Inc., Bio Techne Corp., Halozyme Therapeutics Inc., Takara Bio Inc., Vector Laboratories, New England Biolabs Inc., Protalix Biotherapeutics Inc., Genovis AB, Ludger Ltd, GlycoMar Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/glycomic-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Glycomic Therapeutics Market?

North America was the largest region in the glycomic therapeutics in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomic therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Glycomic Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11894&type=smp

Browse Through More Reports Similar to the Global Glycomic Therapeutics Market 2026, By The Business Research Company

Glycol Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycol-global-market-report

Glycomics Or Glycobiology Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycomics-or-glycobiology-global-market-report

Glycopeptide Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/glycopeptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795